MarketCapExport financials
Anika Therapeutics (ANIK)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Anika Therapeutics Income Statement 2025-2008 | ANIK
Brief overview of revenue and earnings at Anika Therapeutics
The conclusions below are based on five years of reported results. Revenue reported by Anika Therapeutics was 130 million dollars at the beginning of the period and 113 million dollars at the end. The cumulative result was −13.5%, corresponding to roughly −2.9% per year. The business finished the period with a smaller revenue base.
The five-year change in gross profit reached −7.6%: from $69 million to $63.8 million. The cost base moved more slowly than the top line, which supported margins. At the margin level, the figure shifted from 52.9% to 56.6%. A wider margin shows that the economics of the core business improved.
EBITDA changed from −$22.2 million to −$5.7 million (+74.5%). Additional revenue translated efficiently into EBITDA. EBITDA margin moved from −17% to −5%. The increased EBITDA share is a positive sign.
Across the five years, the net result shifted from −$24 million to −$10.9 million. The loss reduction is constructive, but the recovery is incomplete.
Market capitalization changed from $526 million to $214 million (−59.4%). The market is not yet fully reflecting the fundamental progress.
Overall conclusion
The results contain several connected negative signals. The positive side is supported by better sales economics, a stronger final result and higher operating efficiency. The weaker side of the profile includes weak sales momentum, lower investor confidence and limited operating profitability. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Anika Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
214 M | 219 M | 373 M | 406 M | 458 M | 526 M | 606 M | 548 M | 994 M | 730 M | 562 M | 575 M | 472 M | 141 M | 119 M | 77.5 M | 59.2 M | - |
Shares |
14.3 M | 14.7 M | 14.7 M | 14.6 M | 14.4 M | 14.2 M | 14.1 M | 14.4 M | 14.6 M | 14.7 M | 14.9 M | 14.7 M | 14.1 M | 13.3 M | 13.1 M | 12.6 M | 11.4 M | - |
Historical Prices |
14.9 | 14.9 | 25.4 | 27.9 | 31.8 | 37 | 41.1 | 38 | 66.7 | 50.5 | 37.6 | 39.2 | 33.3 | 10.6 | 9.2 | 6.14 | 5.2 | 8.73 |
Net Income |
-10.9 M | -56.4 M | -82.7 M | -14.9 M | 4.13 M | -24 M | 27.2 M | 18.7 M | 31.8 M | 32.5 M | 30.8 M | 38.3 M | 20.6 M | 11.8 M | 8.47 M | 4.32 M | 3.69 M | - |
Revenue |
113 M | 120 M | 121 M | 114 M | 148 M | 130 M | 115 M | 106 M | 113 M | 103 M | 93 M | 106 M | 75.1 M | 71.4 M | 64.8 M | - | - | - |
Cost of Revenue |
49 M | 43.9 M | 38.3 M | 40.6 M | 64.9 M | 61.4 M | 28.7 M | 31.3 M | 27.4 M | 24 M | - | - | - | - | - | - | - | - |
Gross Profit |
63.8 M | 76 M | 82.5 M | 73.2 M | 82.9 M | 69 M | 85.9 M | 74.3 M | 86.1 M | 79.4 M | 71.9 M | 84.7 M | 52.3 M | 42.4 M | 38 M | - | - | - |
Operating Income |
-11.1 M | -5.1 M | 844 K | 3.67 M | 2.62 M | -28.3 M | 34.2 M | 21.7 M | 45.7 M | 50.6 M | 48.1 M | 61.4 M | 32.6 M | 19.7 M | 14 M | 7.54 M | 5.59 M | - |
EBITDA |
-5.68 M | 1.78 M | 7.28 M | 10.4 M | 9.1 M | -22.2 M | 40.2 M | 27.7 M | 50 M | 54.3 M | 51.9 M | 66.2 M | 37.1 M | 26.8 M | 18 M | 10.9 M | 6.88 M | - |
Operating Expenses |
- | - | - | - | - | - | 51.6 M | 52.5 M | 40.3 M | 28.7 M | 23.8 M | 23.2 M | 20 M | 20.1 M | 24 M | - | - | - |
General and Administrative Expenses |
49.1 M | 55.6 M | 59.9 M | 51.2 M | 74.1 M | 60.1 M | 35 M | 34.3 M | 21.5 M | 18 M | 14.8 M | 15.1 M | 12.9 M | 14.7 M | 17.9 M | 17.3 M | 10.5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Anika Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
13.3 M | 13.5 M | 14.4 M | 14.4 M | 14.3 M | 14.4 M | 14.8 M | 14.8 M | 14.7 M | 14.7 M | 14.6 M | 14.7 M | 14.7 M | 14.6 M | 14.6 M | 14.6 M | 14.5 M | 14.4 M | 14.4 M | 14.4 M | 14.3 M | 14.3 M | 14.2 M | 14.2 M | 14.2 M | 14.3 M | 14.1 M | 13.9 M | 14.2 M | 14.2 M | 14.2 M | 14.7 M | 14.7 M | 14.7 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 14.7 M | 14.9 M | 15 M | 15 M | 15 M | 14.9 M | 14.9 M | 14.8 M | 14.7 M | 14.5 M | 14.3 M | 13.7 M | 13.5 M | 13.4 M | 13.3 M | 13.3 M | 13.3 M | 13.2 M | 13.1 M | 12.8 M | 12.7 M | 12.7 M |
Net Income |
3.31 M | -5.06 M | -2.33 M | -3.97 M | -4.87 M | - | -29.9 M | -88 K | -4.51 M | - | -6.58 M | -2.74 M | -10.4 M | - | -4.18 M | -2.84 M | -2.93 M | - | 558 K | 6.53 M | 2.84 M | -15.7 M | -6.41 M | -7.71 M | 5.79 M | 4.05 M | 9.2 M | 9.44 M | 4.51 M | 7.72 M | 7.6 M | 10.1 M | -6.69 M | 8.07 M | 6.89 M | 11.4 M | 5.49 M | 8.08 M | 8.95 M | 8.62 M | 6.9 M | 11 M | 8.38 M | 7.82 M | 3.52 M | 7.82 M | 6.17 M | 9.3 M | 15 M | 6.65 M | 4.96 M | 5.89 M | 3.07 M | 4.46 M | 1.65 M | 3.74 M | 1.91 M | 2.88 M | 2.98 M | 2.28 M | 324 K |
Revenue |
32.6 M | 29.6 M | 27.8 M | 28.2 M | 26.2 M | - | 29.6 M | 30.7 M | 29 M | - | 41.5 M | 44.3 M | 37.9 M | - | 40.3 M | 39.7 M | 36.7 M | - | 39.5 M | 38.1 M | 34.3 M | 32.7 M | 31.7 M | 30.7 M | 35.4 M | 29.8 M | 29.7 M | 30.4 M | 24.7 M | 27 M | 26.8 M | 30.5 M | 21.3 M | 29.4 M | 27.2 M | 33.5 M | 23.4 M | 28.7 M | 25.8 M | 26.6 M | 22.3 M | 30.9 M | 23.7 M | 22.9 M | 15.5 M | 23.3 M | 22.1 M | 26.3 M | 34 M | 21.3 M | 17.8 M | 20.8 M | 15.2 M | 22.6 M | 14.8 M | 19.6 M | 14.4 M | 18.4 M | 18.5 M | 16.1 M | 11.7 M |
Cost of Revenue |
11.4 M | 10.6 M | 12.2 M | 13.9 M | 11.5 M | - | 10.2 M | 10.2 M | 10 M | - | 16.5 M | 15.3 M | 15.1 M | - | 17.5 M | 14.8 M | 14.9 M | - | 16.5 M | 17.3 M | 13.3 M | - | 14.4 M | 16.9 M | 14.2 M | 8.65 M | 5.95 M | 6.84 M | 7.31 M | 7 M | 8.28 M | 8.15 M | 7.84 M | 8.72 M | 6.25 M | 6.32 M | 6.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
21.2 M | 19 M | 15.6 M | 14.4 M | 14.7 M | - | 19.4 M | 20.5 M | 19 M | - | 24.9 M | 29 M | 22.8 M | - | 22.8 M | 24.9 M | 21.8 M | - | 23 M | 20.8 M | 21 M | 16.7 M | 17.3 M | 13.7 M | 21.2 M | 21.1 M | 23.7 M | 23.6 M | 17.4 M | 19.9 M | 18.5 M | 22.4 M | 13.4 M | 20.2 M | 20.9 M | 22 M | 17.3 M | 20.8 M | 20.8 M | 20.5 M | 16.9 M | 19.3 M | 18.5 M | 17.6 M | 11.2 M | 12.4 M | 16.2 M | 15.9 M | 9.99 M | 14 M | 11.6 M | 13.8 M | 9.65 M | 14.2 M | 6.83 M | 10.8 M | 7.2 M | 10.6 M | 10.4 M | 8.76 M | 5.46 M |
Operating Income |
2.95 M | -5.49 M | -3.23 M | -4.18 M | -4.28 M | - | -81 K | -1.81 M | -2.5 M | - | -7.67 M | -3.63 M | -12.6 M | - | -5.8 M | -3.38 M | -3.55 M | - | 1.3 M | 9.18 M | 1.26 M | - | -7.93 M | -9.54 M | 7.09 M | - | 12 M | 11.9 M | 5.48 M | - | 8.57 M | 11.2 M | -7.83 M | - | 10.3 M | 17.7 M | 8.01 M | - | 13.7 M | 13.5 M | 10.7 M | - | 13.1 M | 12.4 M | 5.5 M | - | 10.3 M | 15.2 M | 23.9 M | - | 7.77 M | 9.4 M | 5.01 M | - | 2.73 M | 6.13 M | 3.06 M | - | 4.82 M | 3.68 M | 557 K |
EBITDA |
5.87 M | -4.08 M | 821 K | -1.52 M | -2.9 M | - | 1.22 M | -610 K | -771 K | - | -5.77 M | -1.63 M | -10.9 M | - | -814 K | -1.48 M | -1.88 M | - | 6 M | 11.2 M | 2.8 M | - | -3.38 M | -3.08 M | 9.86 M | - | 16.5 M | 14.9 M | 6.96 M | - | 13 M | 14.2 M | -6.36 M | - | 13.5 M | 19.7 M | 9.02 M | - | 16.5 M | 15.4 M | 11.7 M | - | 15.9 M | 14.3 M | 6.42 M | - | 13.9 M | 17.6 M | 25.1 M | - | 11.3 M | 11.7 M | 6.21 M | - | 6.09 M | 8.32 M | 4.05 M | - | 7.76 M | 5.62 M | 1.48 M |
General and Administrative Expenses |
10.9 M | 17.8 M | 11.9 M | 12.2 M | 12.9 M | - | 13.5 M | 15.6 M | 15.1 M | - | 24.8 M | 23.7 M | 27 M | - | 21.3 M | 21.3 M | 19.2 M | - | 17.5 M | 18 M | 18.2 M | - | 15.9 M | 14.6 M | 14.4 M | - | 7.54 M | 7.5 M | 7.67 M | - | 5.7 M | 6.42 M | 16.1 M | - | 4.82 M | 4.97 M | 5.07 M | - | 4.28 M | 4.26 M | 3.99 M | - | 3.31 M | 3.39 M | 3.6 M | - | 4.04 M | 3.87 M | 3.49 M | - | 3.19 M | 3.4 M | 3.95 M | - | 3.6 M | 4.11 M | 3.35 M | - | 4.71 M | 4.23 M | 4.04 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Anika Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
Israel
Spain
Germany
Australia
Britain
